Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02721875

Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The objectives of this trial are to evaluate the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics and preliminary efficacy of volasertib in two dosing schedules of intravenous volasertib as monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome (MDS) after hypomethylating agents (HMA) treatment failure.

Status: 
Not yet recruiting
Study Date: 
Sat, 04/30/2016 to Sun, 10/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Volasertib Drug: Azacitidine